



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|  |   |    |   |
|--|---|----|---|
| (51) International Patent Classification 3 :<br><br>A61K 31/00   |   | A1 | (11) International Publication Number: <b>WO 85/ 00969</b><br><br>(43) International Publication Date: 14 March 1985 (14.03.85) |
| (21) International Application Number: PCT/US84/01375  | (81) Designated States: AT, AT (European patent), AU, BE (European patent), BR, CH (European patent), DE (European patent), DK, FR (European patent), GB (European patent), JP, LU (European patent), NL (European patent), NO, SE (European patent). |    |   |
| (22) International Filing Date: 29 August 1984 (29.08.84)  |   |    |   |
| (31) Priority Application Number: 528,058  |   |    |   |
| (32) Priority Date: 31 August 1983 (31.08.83)  | Published   |    | <i>With international search report.</i>  |
| (33) Priority Country: US  |   |    |   |
| (71) Applicant: S.K.Y. POLYMERS INC. [US/US]; 1225 State Road, Princeton, NJ 08450 (US).   |   |    |   |
| (72) Inventors: STOY, Deladimir ; 8 Route Road, Princeton, NJ 08540 (US). CHVAPIL, Milos ; 5655 North Minna Vista Road, Tuscon, AZ 85718 (US). |   |    |   |
| (74) Agent: MAYER, Richard, L.; Kenyon & Kenyon, One Broadway, New York, NY 10004 (US).  |   |    |   |

## (54) Title: INJECTABLE PHYSIOLOGICALLY ACCEPTABLE POLYMERIC COMPOSITIONS

## (57) Abstract

Novel physiologically acceptable polymeric compositions and methods of using the same. Numerous polymeric compositions have been tried as alloplastic implants in mammals. They are disadvantageous because they require surgical implantation, they are not integratable into surrounding tissues and their size and shape must be predetermined. Initial attempts to use solidifying compositions were dental filling materials, bone cements and tissue adhesives. Polisiloxane gels were found to leach low-molecular weight compounds into surrounding tissues. Solidifying compositions of bovine collagen solutions were resorbed over time. Disclosed is a non-toxic physiologically acceptable polymeric composition, comprised of water insoluble non-cross linked polymeric compounds, whose solubility is between 9.2 and 15.5 (cal/cc)<sup>1/2</sup>, dissolved in a polar, non-toxic water miscible solvent. The composition solidifies when placed in contact with living tissue. Its principal uses include fillings for ducts or cavities and reinforcements and connections for tissues.

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

|    |                                       |    |                          |
|----|---------------------------------------|----|--------------------------|
| AT | Austria                               | KR | Republic of Corea        |
| AU | Australia                             | LI | Liechtenstein            |
| BE | Belgium                               | LK | Sri Lanka                |
| BG | Bulgaria                              | LU | Luxembourg               |
| BR | Brazil                                | MC | Monaco                   |
| CF | Central African Republic              | MG | Madagascar               |
| CG | Congo                                 | MR | Mauritania               |
| CH | Switzerland                           | MW | Malawi                   |
| CM | Cameroon                              | NL | Netherlands              |
| DE | Germany, Federal Republic of          | NO | Norway                   |
| DK | Denmark                               | RO | Romania                  |
| FI | Finland                               | SD | Sudan                    |
| FR | France                                | SE | Sweden                   |
| GA | Gabon                                 | SN | Senegal                  |
| GB | United Kingdom                        | SU | Soviet Union             |
| HU | Hungary                               | TD | Chad                     |
| JP | Japan                                 | TG | Togo                     |
| KP | Democratic People's Republic of Korea | US | United States of America |

-1-

INJECTABLE PHYSIOLOGICALLY-  
ACCEPTABLE POLYMERIC COMPOSITIONS

FIELD OF INVENTION

5 This invention relates to a novel polymeric composition, and more particularly to a novel physiologically-acceptable polymeric composition and methods for using same.

BACKGROUND

10 Numerous polymeric compositions have been used as alloplastic implants in mammals for the following purposes:

1) to augment tissue deficiency (e.g. in reconstructive facial surgery, mammary augmentation, etc.);

15 2) to replace a functional body component, such as articular cartilage, bone, joint, blood vessel, trachea, dura matter, intraocular lens, etc.;

3) to connect severed tissue (e.g. sutures and staples);

20 4) to block certain ducts or passages (as in reversible sterilization by the Aldrich procedure); and



-2-

5) to provide a depot for sustained and controlled drug delivery, both local and systematic.

Hydrogels, or the water-swellable but water-insoluble polymers, are among the polymeric substrates which have 5 been used as implantable plastics since they offer, inter alia, certain advantages, e.g. permeability for water-soluble compounds, good biological tolerance and controllable softness and flexibility.

Polymeric implants are formed in defined shapes and 10 sizes as demanded by the specific application. Such pre-shaped forms have several disadvantages. Most significantly, the applications require surgical procedures. Secondly, polymeric implant, as a rule, is encapsulated by collagenous tissue capsule and is not 15 integratable into surrounding tissue; porous polymeric implants may be connected to surrounding tissue by in-growing cells, however, such porous polymeric implants are often prone to calcification, etc. Thirdly, the size and shape of the polymeric implant must be 20 determined in advance and any changes of size and shape are effected by re-implantation.

Initial attempts to utilize solidifying composition were directed to applications, such as, dental filling materials, acrylic bone cements, and tissue adhesives 25 based on polyurethanes and alpha-cyanoacrylates. Subsequently, research was directed to solidifying reactive systems. Initially, soft polysiloxane gels were used which do not solidify but which are, to some extent, injectable while preserving some gel-like 30 properties. Such polysiloxane gels are maintained in place by granulation of the surrounding tissue rather than solidification and suffer from the disadvantages of containing low-molecular compounds, such as cyclic oligomers, which slowly migrate into the organism.



-3-

More recent attempts regarding solidifying compositions utilized an aqueous solution of purified bovine collagens which are injected into the tissue and which gelatinate when heated above 37°C. by collagen

5 transition into fibrilar form without presence of low molecular weight toxic components. Collagen itself, however, is reactive and is gradually degraded by enzymatic reaction and is resorbed after a period of time. Thus, such a gelatinous implant is only a

10 temporary replacement of a pre-formed implant which may be subsequently replaced by natural tissue. There is little control over such natural replacement, and unsatisfactory results occur in many instances.

OBJECTS OF THE INVENTION

15 An object of the present invention is to provide a novel solidifying physiologically-acceptable polymeric composition for implantation.

Another object of the present invention is to provide a novel solidifying physiologically-acceptable polymeric composition permitting of injectable implantation.

Still another object of the present invention is to provide a novel solidifying physiologically-acceptable polymeric composition obviating surgical implantation.

A further object of the present invention is to provide

25 a novel solidifying physiologically-acceptable polymeric composition formed of non-toxic materials.

Still yet another object of the present invention is to provide a novel solidifying physiologically-acceptable polymeric composition inert to enzymatic attack.

30 SUMMARY OF THE INVENTION



-4-

These and other objects of the present invention are achieved by the use of non-toxic physiologically-acceptable polymeric composition comprising water insoluble, non-crosslinked polymeric compounds having a 5 solubility parameter between 9.2 and 15.5 (cal/cc)<sup>1/2</sup> dissolved in a polar, non-toxic water miscible solvent, which polymeric composition solidifies when placed in contact with living tissue by absorption of water and by gradual release of solvent into the surrounding tissue.

10 DETAILED DESCRIPTION OF THE INVENTION

The polymeric compounds suitable for the present invention are the water insoluble, non-crosslinked polymers and copolymers having a solubility parameter of between about 9.2 and 15.5 (cal/cc)<sup>1/2</sup>, preferably 15 between 10 to 13.5 (cal/cm)<sup>1/2</sup> See J. Paint Technol. 42, 76 (1970).

1. The polymeric compound must be insoluble in water or blood serum below temperature of about 50°C., and advantageously below 100°C.;

20 2. The polymeric compound must be free of toxic low-molecular components, such as residual monomers, residual initiators, stabilizers or other additives in concentration which could be harmful;

3. The polymeric compound must be soluble in the 25 solvent or solvent system at temperature below about 40°C.; and

4. The polymeric compound in solution and after 30 injection results in an integral form of polymer containing between 25 to 95% by weight water, preferably between 45 to 95% by weight water. Examples of such polymeric compounds are: polymers and copolymers of acrylonitrile, particularly copolymers with other



derivatives of acrylic acid, such as acrylamide, N-substituted acrylamide, acrylhydrazide N-substituted acrylhydrazide, glutarimide, vinylsulfonate acid, acrylic acid and its salts; polyvinylacetate, its 5 copolymers and particularly poly (vinylacetate-co-vinylalcohol); linear or slightly branched polymers and copolymers of 2-hydroxyethyl acrylate and methylacrylate; poly (N-vinyliminocarbonyl); and polycondensates and polyadducts, such as 10 poly(oxyethyleneoxy carbonylimino-1,3-phenyleniminocarbonyl); poly(oxy-1,4-phenylensulfonyl-1,4-phenylene) poly(imino(1-oxoundecamethylene); poly(pyromellitic dianhydride-co-aromatic amines), or polyimic acid. Preferably such polymeric compounds are 15 those which are soluble in dimethylsulfoxide DMSO but insoluble in water, as more fully hereinafter discussed.

Particularly advantageous polymeric compounds are those containing at least 2% nitrile groups, such as the polacrylonitrile and copolymers of acrylonitrile with 20 various, particularly hydrophilic comonomers. A particularly advantageous acrylonitrile copolymer is produced by the partial acid-catalyzed hydrolysis of a polymer containing at least 85 molar percent acrylonitrile units. Polyacrylonitrile and its 25 copolymers, if coagulated from solution of sufficiently high viscosity, forms pseudo-hydrogels (or "aquagels"). The aquagel contains up to about 75% of water, more usually 30 to 60% of water. The water acts as a plasticizer, even if the polymer itself is non-swellable 30 and essentially\* an unlimited time period. Such an aquagel thus formed in tissue is a semirigid material

\* hydrophobic. The water content is not in equilibrium as is the case with true hydrogels. Once the polymer is "dried", the resulting polymeric material cannot regain its original water content. The poly-acrylonitrile-type polymers when coagulated in tissue maintain their water content for essentially.



suitable, for example, for facial bone augmentation.

Hydrogels suitable for the invention are copolymers containing both hydrophilic and hydrophobic groups, such as vinylacetate-vinylalcohol or acryonitrile-acrylamide.

5 More particularly suitable are copolymers in which both hydrophobic and hydrophilic groups are organized in continuous sequences, or block copolymers, such as described in U.S. Patent No. 4,379,874, U.S. Patent No. 4,420,589; U.S. Patent No. 4,331,783; U.S. Patent No. 10 4,337,327; and U.S. Patent No. 4,370,451 (incorporated herein by reference) and which are particularly suited for the present invention.

The solvent or solvent system of the present invention for the above polymeric compounds should be polar, 15 miscible with water and non-toxic. Preferred solvents for the present invention are the non-toxic water-miscible solvents having a molecular weight below about 200, exhibiting moderate to strong hydrogen-bonding capability and having a preferred solubility parameter 20 between 10 and 15 (cal/cc)<sup>1/2</sup> for moderately H-bonding and between 11 and 20, e.g. between 12.5 to 17) for stronger H-bonding. Examples of such solvents are dimethyl sulfoxide (DMSO), glycerol, glycerol monoacetate, glycerol diacetate (diacetin), methanol, 25 ethanol, propanol, iso-propanol, cyclic ethylene carbonate, cyclic propylene carbonate, dimethyl formamide, tetramethylene sulfoxide, N-N-diethylacetamide, N,N,-dimethylacetamide, ethylene glycol, propylene glycol, triethylene glycol and 30 diethylene glycol and mixtures thereof.

The polymeric compound is admixed with the solvent in a concentration of from about 0.1 to 50% by weight, such that the resulting polymeric solution when in contact with water forms an integral solid (homogeneous or



porous), and in no event forms a dispersion of solid polymer particles. In other words, the polymeric solution coagulates rather than precipitates when its contacts water. Such coagulation property related to 5 the solution viscosity, which is, in turn, is determined by the molecular weight of the polymeric compound, its concentration and temperature. The viscosity of these compositions ranges from about 15 centipoises to about 20,000 centipoises. The concentration of the polymeric 10 compound with solvent suitable for an injectable polymeric composition decreases with increasing molecular weight of the polymeric compound. Coagulation of the polymeric compound in contact with water is reversible, and is a purely physical process without any 15 associated chemical change in the polymeric compound. The coagulated polymeric compound can be redissolved in the same or a similar solvent.

For certain applications to modify mechanical properties of the resulting polymer and to provide opacity, it is 20 desireable to add as a filler up to 50% by weight of an inorganic material in powder form to the polymeric composition. Such inorganic filler materials include calcium sulfate, barium sulfate, apatite, hydroxyapatite, aluminum hydrate and silicon dioxide.

25 The polymeric composition of the present invention may also include a biologically active substance to effect certain results, e.g. thrombine may be added to effect coagulation at the injected site, collagen may be added to provide a support site, etc. Advantageously, any 30 such biologically active substance should be substantially soluble in the solvent or solvent system but essentially insoluble in water.



The solidification of a polymeric form upon injection of the polymeric composition solution into the tissue and without damage to the surrounding tissue is surprising since it is known that cell membranes are highly  
5 sensitive to the osmotic pressure imposed by a difference in concentrations of water-soluble compounds within and outside the cell. The osmotic equilibrium can also cause dehydration of cells which is equally damaging. Yet the cells survive the solidification of  
10 the resulting polymeric form even directly in intercellular space.

One possible explanation of such a finding is that the outermost layer of solution coagulates by intercellular liquid, having an equilibrium content readily  
15 replenished via lymphatic system. The polymer "skin" thus formed takes over the major part of the concentration gradient. In other words, the barrier of the coagulated polymers controls the water and solvent permeation rates before a substantial pressure gradient  
20 across the cell wall can be established. This hypothesis, however, is not to be construed as limiting this invention.

The polymer solutions can be used in various medical situations. Typically, the polymeric composition or  
25 solutions yielding hydrogel upon the coagulation by the tissue fluids can be injected intradermally (i.d.) or subcutaneously (s.c.) to remove cosmetic skin defects or adjust facial contours (e.g. acne or pox scars, wrinkles, etc.) Most suitable for this particular  
30 application is a polymeric solution formed of from 5 to 25% by weight of a multiblock copolymer of acrylonitrile and/or acrylic acid, such as described, in the aforementioned U.S. Patent No. 4,379,874, dissolved in dimethylsulfoxide and more particularly, 7.5 to 12.5% by



weight. Such a resulting polymeric form exhibits a swelling capacity of from 50 to 97%, advantageously 70 to 92% in equilibrium with water.

5 The advantage of such specific formulation for this particular field of use in that the subcutaneously or intradermally injected polymeric solution does not solidify instantaneously, but can be shaped by pressure on skin several minutes following injection. This allows for contour adjustment without reinjection.

10 Another advantage is that the hydrogel interpenetrates tissue cells without prevalent tissue reactions, such as encapsulation or fibrosis. Therefore, the repaired site remains soft and of constant size and shape without hardening or constriction in the course of time. The

15 15 solidified hydrogel is embedded in intercellular spaces so that it is firmly anchored and cannot migrate. Finally, the hydrogel is enzymatically stable and does not degrade nor can be resorbed.

20 True hydrogels (swelling to an equilibrium in contact with water) are particularly advantageous for replacement and augmentation of soft tissue, as a filler of body cavities and the like. Such a hydrogel is elastic with elasticity increasing with increasing water content. Additionally water uptake compensates for loss 25 of solvent. The resulting hydrogel formed in the tissue may have a lower or higher volume than the injected solution, depending on the solution concentration and the final (equilibrium) swelling of the hydrogel.

30 Formulations of similar composition are also useful as fillers or blocks of ducts or cavities. In this case, the polymeric composition as solution is injected into a duct or cavity wall. The resulting polymeric form is not embedded in the intracellular space, but is clearly separated from the tissue. It is important for the



-10-

polymeric form to entirely fill the duct or cavity. Therefore, the resulting polymeric form or material must not shrink upon solidification. On the contrary, mild expansion of the polymeric form or material is 5 advantageous. This is achieved by selecting the appropriate polymeric form with appropriate water uptake or by adjusting the polymeric concentration in the polymeric solution or a combination of both. Generally, the volume fraction of polymeric compound in the 10 polymeric solution is to be equal or higher than in the final hydrogel. Examples of uses of such solutions are in connection with reversible male or female sterilization, i.e. injection of the polymeric composition into the vas deferens or Fallopian tubes, 15 respectively.

Another use of the injectable polymeric composition or solution is in connection with the reinforcement or the strengthening of deficient tissues, such as tendons, joint capsules, ligaments or blood vessel walls. The 20 formulations useful in this field are those yielding hydrogels or aquagels with medium water content (20 to 65% of water) and high mechanical strength.

Still another use of the polymeric composition or solution of the present invention is the connection of 25 severed tissues by injection into both tissue parts simultaneously or consecutively of such a polymeric composition or solution. The aquagels or hydrogels with moderate swelling are advantageous because contraction during solidification helps to hold the severed parts 30 firmly yet gently together. Such a use is particularly desirable for connecting very soft tissue where sutures or surgical staples cannot be used.



Injection of the polymeric composition can be used also for strengthening and reinforcing soft or lacerated tissue (such as liver or spleen), unable to hold sutures or staples. Soft tissue which has been reinforced in 5 this manner can be surgically dissected without excessive bleeding.

Similar injectable polymeric compositions can be used for permanent connection between tissue and an alloplastic material, such as a plastic gate for 10 peritoneal dialysis. Such permanent connection prevents penetration of infection along the tissue/plastic interface.

While the above mentioned compositions are exceptionally well-tolerated in a variety of applications, it has been 15 found that, in some specific types of situations, some mild side effects can be associated with their use. Under such circumstances, a slightly modified form of these polymeric compositions which will substantially avoid such side effects can be used. These modified 20 compositions can be obtained by the pre-dilution of the polymer with water or a water/alcohol solution. Another modification comprises the addition of a hydrophobic "skin forming" component. Often, it is advantageous to both pre-dilute and add a "skin forming" component. 25 These modified compositions result in a polymeric composition that is even less likely to cause side reactions than the unmodified forms.

The side effects which may temporarily occur following subdermal or subcutaneous injection of the unmodified 30 form are erythema (reddening of the injected site), temporary swelling (in addition to permanent volume change caused by polymer itself) and tissue reaction



-12-

(inflammatory reaction occasionally in exceptionally high dosages of the unmodified form, prenecrotic states and, in rare, worst cases, local necrosis can occur).

All the above effects are temporary, and even injections 5 which result in local necrosis ultimately heal so that after a certain time the sites could not be distinguished from those without the initial tissue reaction. However, investigation has revealed that 1) reaction was more severe in ventral than dorsal aspect 10 of test animals, 2) reaction was more likely to be severe for intradermal than subcutaneous, injection, while injection into internal ducts, veins or internal organs caused no observable problem, 3) reaction increased with increasing injected volume. While 15 injection of volumes up to 0.2 ml in single injections s.c. showed few side effects, injections s.c. larger than 0.2 ml and i.d. larger than 0.05 ml caused effects with severity increasing with increasing dose.

Evaluation of these experiments reveals that these side 20 reactions have two principal causes: damage of cells by osmotic shock and damage of cells by hydraulic shock.

It has been found that the osmotic shock can be diminished by pre-dilution of the solvent with water which decreases the concentration gradient of water 25 across the cellular wall. In addition, the predilution by water accelerates the formation of a barrier between cells and the coagulated polymer. Such a barrier will diminish the osmotic shock by slowing the release rate of the solvent so that it can be more efficiently 30 diluted by body fluids.

The effect of the solvent is lesser in locations with ample fluid supply, such as internal organs, ducts or blood vessels.



The effect of the solvent is greater in locations with ample fluid supply, such as internal organs, ducts or blood vessels.

5 Polymers particularly suitable for use in combination with aqueous solvents are linear or slightly branched polymers and copolymers of 2-hydroxyethyl acrylate and methacrylate, which are quite soluble in aqueous ethanol, isopropanol, in aqueous glycerol, aqueous 1,2-propyleneglycol or in aqueous DMSO.

10 It has been found that aqueous solvents dissolve such polymers much better than an anhydrous solvent. The reason for this is believed to be the fact that the solvents break water associates so that activity of -OH groups in the cosolvent mixture is greater than in pure water. The maximum solubility for the polymer in a cosolvent mixture corresponds to a molar ratio of water to the non-aqueous cosolvent of about 1, though polymers are usually soluble in broad range of solvent compositions. For instance, poly (2-hydroxyethyl 15 methacrylate) can be readily dissolved in solvents containing ethyl alcohol or DMSO and up to about 65 wt-% of water. Suitable amounts of aqueous solvent can be as high as 70% and preferably up to 55% when hydrophilic polyacrylates and polymethacrylates are used. When 20 derivatives or co-polymers of polyvinyl alcohol are used, up to 60% is useful, preferably up to 50%. Nitrile-containing systems may be used with up to 40% 25 aqueous solvent, preferably up to 30%.

Another feature of these polymers is their relatively 30 slow coagulation when their solution is mixed with water. The spongeous polymer structure is formed relatively slowly, forming first very soft semiliquid gel which gradually sets into hydrogel capable of plastic deformation. This makes these polymers



-14-

particularly well suited for application into stiff tissues and other environments where mechanical strength of the resulting hydrogel is not a primary consideration. Examples of such use include

5 subcutaneous or intradermal injection to correct skin defects, such as acne scars or wrinkles.

Polymers with similar solubility characteristics and similar uses as the polymers above are polymers and copolymers of N-substituted acrylamides soluble in

10 alcohols, glycerine or 1,2 propylene glycol but insoluble in water.

An example of such a polymer is the product of the reaction of poly (2,4-glutarimide) with octadecylamine and 3-aminopropylmorpholin, which is insoluble in water

15 but soluble in aqueous glycerol.

Another group of compositions suitable for subcutaneous and intradermal applications are multiblock copolymers of acrylonitrile with predominant amount of acrylamide and advantageously other substituents such as methyl

20 acrylate, acrylic acid or acrylate, or N-substituted acrylamide or acrylhydrazide. The content of acrylonitrile units is between 3 and 25%, advantageously between 5 and 15 mole %. Acrylamide units form at least 50% of the non-acrylonitrile units. Such copolymers can

25 be prepared by acid- or acid base-catalyzed hydrolysis of polymers and copolymers of acrylonitrile, or more advantageously from block copolymers of acrylonitrile-glutarimide (described in U.S.P. 4,331,783) by reactions described in US Patent 4,337,327 and 4,370,451, the

30 disclosures of which are incorporated by reference.

The molecular weight of such copolymers is advantageously kept low to keep viscosity of the solution low, for example, in the range of about 15 to



500 centipoises. A viscosity in the range of 45 to 300 centipoises is preferred for these applications. Typical molecular weight of such copolymers for subcutaneous or intradermal injections is between 50,000 5 to 150,000. Concentration of such polymers in injectable compositions is between 2 and 25 by weight, the lower concentration limit being suitable for higher molecular weight limit and vice versa. Such copolymers are preferably dissolved in DMSO, which can contain up 10 to about 30% by wt. of water to diminish the osmotic shock.

The dilution of DMSO by water in the compositions containing the above described acrylonitrile-containing multiblock copolymer decreases the osmotic shock both 15 directly (by decreasing concentration gradient of water between the cell and the solvent) and indirectly. The indirect effect consists in accelerated coagulation of the polymer to form the tissue protecting barrier. This can be utilized particularly for injection into soft 20 tissues, ducts, cavities and vessels where effects of hydraulic pressure are not significant.

It has now been found that certain polymer solutions coagulate in contact with water in a particularly advantageous manner. Solutions of mixtures of larger 25 portion of hydrophilic polymer and smaller portion of hydrophobic polymer form fine surface skin in contact with water. The skin has low permeability and thereby effectively protects surrounding tissue from osmotic shock. The initially-formed skin is very thin (thinner 30 films are produced by less permeable compositions) so that it does not substantially increase the resistance of the tissue to the penetration of the solution. It is believed that the fast surface coagulation diminishes the osmotic shock without undesirable simultaneous 35 increase in hydraulic pressure during injection.



Typical aqueous solutions with such coagulation behavior are compositions of highly hydrophobic multiblock copolymers of acrylonitrile mixed with polacrylonitrile as described in USP 4,379,874 dissolved in DMSO.

- 5 Another example is a mixture of hydrophilic vinyl alcohol/vinyl acetate copolymer with polyvinyl acetate. The solvents of the above composition can be diluted with water so that viscosity of the solution does not exceed the preferred values set forth above and the
- 10 polymer separation does not take place in the solution. The dilution with water accelerates the skin formation and diminishes osmotic shock still further.

EXAMPLE 1

Multiblock acrylonitrile hydrogel was prepared by

- 15 partial hydrolysis of polyacrylonitrile (MW - 150,000) dissolved in a mixture of sulphuric and phosphoric acid at 35°C. After the desired conversion of hydrolysis was reached, the polymer solution was extruded into an excess of water and the coagulated hydrogel was
- 20 thoroughly washed and then dried. Dry polymer was dissolved in DMSO to form 10% of weight solution, cast into thin foil and coagulated with water. After thoroughly washed, the hydrogel contained 90% of weight of water. Sections of hydrogel film were soaked in DMSO
- 25 diluted with water to 100%, 75% and 25% of DMSO. Then 0.5 gram portions of the DMSO-swollen gel were implanted subcutaneously in the abdominal region of rats through a small skin incision. Skin reaction was observed twice daily for 3 days, at which time it was sampled for
- 30 histological evaluation.

The multiblock hydrogel was also dissolved in DMSO to form solutions of 5% by weight, and 10% by weight of the polymer.



-17-

Poly ( 2-hydroxyethyl methacrylate (PHEMA)), prepared by polymerization of highly purified monomer, was dissolved in DMSO to form a 10% by weight solution.

The foregoing solutions were injected subcutaneously 5 into abdominal region of rats in volumes ranging from 0.1 to 0.5 ml.

As a control, DMSO undiluted and diluted with water to 75%, 50% and 25% by volume of DMSO was injected into the abdominal region of rats (0.5 ml subcutaneously).

10 The results show that:

- 1) DMSO imbibed in the hydrogel causes no adverse reaction, even for undiluted DMSO.
- 2) The 10% solution of the same polymer in DMSO causes strong reddening (erythema) and tissue reaction for 15 injections of volumes of 0.2 ml or more.
- 3) 5% solution of the same polymer in DMSO causes mild erythema and minimal tissue reaction around a homogeneous hydrogel implant.
- 4) 10% solution of PHEMA in DMSO causes no erythema and 20 minimum tissue reaction around the spongy hydrogel.
- 5) Injection of DMSO at a concentration of 75% or 100% causes strong erythema and tissue reaction resulting in necrosis.

The conclusion reached was that the polymer protects the 25 tissue against solvent shock; lower solution viscosity is desirable (PHEMA and 5% versus 10% concentration of the acrylic hydrogel) to prevent side effects of hydraulic pressure resulting from injection.



EXAMPLE 2

The multiblock copolymer of acrylonitrile and acrylamide was prepared as described in Example 1 at 30°C. The lower conversion of hydrolysis caused that equilibrium 5 water content to be 55% by wt. Ten wt. parts of the copolymer was dissolved in 90. wt. parts of DMSO. The solution was used in various experiments with the following results:

- 1) 0.5 ml of the solution was injected into the uterine 10 horn of a female rat through the uterine wall. The solution solidified into the firm yet flexible hydrogel bolus which blocked the Fallopian tube (and thus causing reversible sterility). Histological examination after 7, 33 and 42 days showed no evidence of irritation of the 15 mucous membrane or disruption of the epithelial lining.
- 2) The same polymer solution was injected into dog liver in multiple injections of 0.5 ml each. The hydrogel solidified in the soft liver tissue to form a barrier across one of the lobes. A lobotomy was then 20 carried out essentially without bleeding and the resected liver healed without post-surgery complications.
- 3) The same solution was injected in multiple doses of 0.2-0.5 ml each into lacerated muscle of a rabbit 25 (gunshot wound). The hydrogel solidified in the tissue and bleeding was stopped. The subsequent healing proceeded without complications.
- 4) The same solution was injected subcutaneously into the abdominal region of rats in doses of from 0.1 to 0.5 30 ml. The 0.1 ml injection caused erythema, while doses of 0.2 and higher caused strong erythema and same local tissue necrosis.



-19-

These results indicate that rapidly coagulating and viscous polymer solutions are suitable for injections into internal body cavities and soft and/or bleeding tissues while they are less suitable for injections into 5 more rigid tissues such as skin.

EXAMPLE 3

Poly (2-hydroxyethyl methacrylate)(PHEMA), MW-90,000, was prepared by polymerization of purified monomer (HEMA) solution in water by a hydrogen peroxide 10 initiator. The polymer was purified by reprecipitation from an alcoholic solution into ether and dried. Ten wt. parts of PHEMA was dissolved in 90 wt. parts of 50% aqueous ethanol and injected subcutaneously (s.c.) and intradermally (i.d.) into the abdominal region of a rat, 15 a rabbit and a pig.

The injected volumes up to 0.2 ml s.c. and 0.1 ml i.d. caused no erythema and only negligible tissue reaction. The injected sites slowly diminished in volume until their size stabilized after several hours. The maximum 20 swelling was observed between about 5 minutes and 2 hours, when the injection was still very soft and semi-liquid. After several hours a well defined spongy-looking implant was formed which caused no tissue reaction. The decrease of the injected volume is 25 advantageous for cosmetic applications because it prevents overcorrection.

The lack of erythema and tissue reaction illustrates the beneficial effect of the dilution of solvent with water and the resulting slow coagulation of the polymer.

30 EXAMPLE 4

A copolymer of acrylonitrile (93 mole %) and methylacrylate (7 mole %) MW = 110,000, was hydrolyzed at 30°C in solution in a mixture of phosphoric and



-20-

sulfuric acids. When the desired conversion of hydrolysis was reached, the polymer was coagulated by water, washed and dried. Equilibrium swelling capacity of the hydrogel was 93.5% by wt. of water. The 5 following two solutions were prepared from the hydrolyzate:

A) Ten wt. parts of the polymer were dissolved in 90 wt. parts of 85% aqueous DMSO.

B) 5 wt. parts of the hydrolyzate and 0.5 wt. parts of 10 the starting acrylonitrile copolymer were dissolved in 95 wt. parts of DMSO. Solution A was a higher viscosity than Solution B and coagulates rapidly into clear, soft gel upon contact with water.

The final volume of gel is larger than the volume of the 15 solution. Solution B, in contact with water, forms immediately a very thin opaque "skin" on the surface, while still liquid beneath.

The "skin" is initially very soft and weak but gradually increases in thickness until all of the solution is 20 fully solidified into an opaque, flexible hydrogel. The volume of the final hydrogel is somewhat smaller than that of the original solution.

Both solutions A and B were injected s.c. into dorsal and ventral aspects of rats. Solution A was well 25 tolerated up to 0.3 ml on the dorsal side up to 0.2 ml on the ventral side, while solution B was tolerated up to 0.5 ml and 0.3 ml on the dorsal and the ventral side, respectively. The typical injected volume in a facial cosmetic application is up to 0.1 ml in a single 30 injection.



-21-

Both solutions A and B could be formed for a time after injection by mild pressure across the skin, indicating that at least part of the injected solution is still liquid. Solution A solidified substantially faster than  
5 solution B.



WHAT IS CLAIMED IS

1. A novel physiologically-acceptable polymeric composition comprised of a polymeric compound dissolved in a water soluble, non-toxic, polar solvent, said polymeric compound comprised of water insoluble, non-toxic, non-crosslinked polymer or copolymer having a solubility parameter of from about 9.2 to about 15.5 (cal/cc)<sup>1/2</sup>.
2. The physiologically-acceptable polymeric composition as defined in Claim 1 wherein said polymeric compound is insoluble in blood serum below about 50°C.
3. The physiologically-acceptable polymeric composition as defined in Claim 2 wherein said polymeric compound is insoluble in blood serum below about 100°C.
4. The physiologically-acceptable polymeric composition as defined in Claim 2 wherein said polymeric compound is soluble in said solvent at temperatures below 40°C.
5. The physiologically-acceptable polymeric composition as defined in Claim 1 wherein said polymeric compound is selected from the group consisting of polymers and copolymers of acrylonitrile, polyvinylacetate, copolymers of polyvinylacetate, linear or slightly branched polymers and copolymers of 2-hydroxyethyl acrylate and methylacrylate, poly(N-vinyliminocarbonyl), polycondensates and polyadducts.



-23-

6. The physiologically-acceptable polymeric composition as defined in Claim 5 wherein said water insoluble non-cross linked polymer contains at least 2 weight percent nitrile groups.
7. The physiologically-acceptable polymeric composition as defined in Claim 6 wherein said polymeric compound is a copolymer of acrylonitrile with a derivative of acrylic acid and selected from the group consisting of acrylamide, N-substituted acrylamide, acrylhydrazide, N-substituted acrylhydrazide, acrylic acid, acrylic acid salts, glutarimide and vinylsulfonate.
8. The physiologically-acceptable polymeric composition as defined in Claim 5 wherein said copolymer of polyvinylacetate is poly (vinylacetate-co-vinylalcohol).
9. The physiologically-acceptable polymeric composition as defined in Claim 1 wherein said solvent has a molecular weight below about 200 and exhibits at least moderate hydrogen bonding ability.
10. The physiologically-acceptable polymeric composition as defined in Claim 5 wherein said acrylonitrile containing copolymer is produced by the partial acid-catalyzed hydrolysis of a polymer containing at least 85 molar percent of acrylonitrile units.
11. The physiologically-acceptable polymeric composition as defined in Claim 9 wherein said solvent is selected from the group consisting of dimethyl sulfoxide (DMSO), glycerol, glycerol monoacetate, glycerol diacetate (diacetin),



-24-

methanol, ethanol, propanol, iso-propanol, cyclic ethylene carbonate, cyclic propylene carbonate, dimethyl formamide, tetramethylene sulfoxide, N-N-diethylacetamide, N,N,-dimethylacetamide, ethylene glycol, propylene glycol, triethylene glycol and diethylene glycol and mixtures thereof.

12. The physiologically-acceptable polymeric composition as defined in Claim 11 wherein said solvent is dimethylsulfoxide.
13. The physiologically-acceptable polymeric composition as defined in Claim 1 wherein said polymeric compound is in a concentration of from 0.1 to 50 percent by weight.
14. A method of treating a mammal which comprises injecting into said mammal a physiologically-acceptable polymeric composition comprised of a polymeric compound dissolved in a water soluble, non-toxic polar solvent, said polymeric compound comprised of a water insoluble, non-toxic, crosslinked polymer or copolymer having a solubility parameter of from about 9.2 to about 15.5 (cal/cc)<sup>1/2</sup>.
15. The method of treating a mammal as defined in Claim 14 wherein said polymeric compound is insoluble in blood serum below about 50°C.
16. The method of treating a mammal as defined in Claim 15 wherein said polymeric compound is insoluble in blood serum below about 50°C.
17. The method of treating a mammal as defined in Claim 16 wherein said polymeric compound is soluble in said solvent at temperatures below 40°C.



-25-

18. The method of treating a mammal as defined in Claim 14 wherein said polymeric compound is selected from the group consisting of polymers and copolymers of acrylonitrile, polyvinylacetate, copolymers of polyvinylacetate, linear or slightly branched polymers and copolymers of 2-hydroxyethylacrylate and methylacrylate, poly (n-vinyliminocarbonyl), polycondensates and polyadducts.
19. The method of treating a mammal as defined in Claim 18 wherein said polymeric compound is a copolymer of acrylonitrile with a derivative of acrylic acid and selected from the group consisting of acrylamide, N-substituted acrylamide, acrylhydrazide, N-substituted acrylhydrazide, acrylic acid, acrylic acid salts, glutarimide and vinylsulfonate.
20. The method of treating a mammal as defined in Claim 18 wherein said copolymer of polyvinylacetate is poly(vinylacetate-co-vinylalcohol).
21. The method of treating a mammal as defined in Claim 14 wherein said solvent has a molecular weight below about 200 and exhibits at least a moderate hydrogen bonding ability.
22. The method of treating a mammal as defined in Claim 21 wherein said solvent is selected from the group consisting of dimethyl sulfoxide (DMSO), glycerol, glycerol monoacetate, glycerol diacetate (diacetin), methanol, ethanol, propanol, isopropanol, cyclic ethylene carbonate, cyclic propylene carbonate, dimethyl formamide, tetramethylene sulfoxide, N-N-diethylacetamide,



-26-

N,N,-dimethylacetamide, ethylene glycol, propylene glycol, triethylene glycol and diethylene glycol and mixtures thereof.

23. The method of treating a mammal as defined in Claim 21 wherein said solvent is dimethylsulfoxide.
24. The method of treating a mammal as defined in Claim 23 wherein said polymeric compound is in a concentration of from 0.1 to 50 percent by weight.
25. The method of treating a mammal as defined in Claim 18 wherein said water insoluble non-cross linked polymer contains at least 2 weight percent nitrile groups.
26. The method as defined in Claim 14 wherein said acrylonitrile-containing copolymer is produced by the partial acid-catalyzed hydrolysis of a polymer containing at least 85 molar percent of acrylonitrile units.
27. The method as defined in Claim 18 wherein said polymeric composition after injection results in a polymeric form containing from 25 to 99 percent by weight water.
28. The method as defined in Claim 27 wherein said polymeric form contains from 45 to 95 percent by weight water.
29. The method as defined in Claim 28 wherein said polymeric composition, after injection, results in a polymeric form containing from 50 to 99 percent by weight water.



-27-

30. The method as defined in Claim 29 wherein said polymeric form contains 70 to 95 percent by weight water.
31. The composition of claims 1 through 13 comprising water in admixture with said polymer and said water soluble, nontoxic polar solvent.
32. The composition of claim 31 wherein about 4 to about 20 weight parts of said water and nontoxic polar solvent are used for each weight part of polymer.
33. The composition of claim 31 wherein said water and nontoxic polar solvent is an aqueous solution of an alcohol.
34. The composition of claim 33 wherein said alcohol is ethanol.
35. The composition of claim 34 wherein said solution contains 50% ethanol by weight.
36. The composition of claim 34 wherein 90 weight parts of aqueous solution is used per 10 weight parts of polymer.
37. The composition of claim 1 through 13 or 31 further comprising a hydrophobic polymer in sufficient quantity to cause the formation of surface skin around the injected composition when introduced into a patient.



-28-

38. The composition of claim 37 wherein said hydrophobic polymer is selected from the group consisting of multiblock polymers of acrylonitrile and a mixture of a hydrophilic copolymer of vinyl alcohol/vinyl acetate with polyvinylacetate.



# INTERNATIONAL SEARCH REPORT

International Application No. **PCT/US84/01375**

## **I. CLASSIFICATION OF SUBJECT MATTER** (if several classification symbols apply, indicate all) <sup>3</sup>

According to International Patent Classification (IPC) or to both National Classification and IPC **9**

**A 61K 31/00**

## **II. FIELDS SEARCHED**

Minimum Documentation Searched <sup>4</sup>

| Classification System | Classification Symbols |                       |
|-----------------------|------------------------|-----------------------|
| U.S.                  | 424/78, 81<br>526/230  | 604/368, 55, 336, 891 |

Documentation Searched other than Minimum Documentation  
to the Extent that such Documents are Included in the Fields Searched <sup>5</sup>

## **III. DOCUMENTS CONSIDERED TO BE RELEVANT** <sup>14</sup>

| Category <sup>6</sup> | Citation of Document, <sup>16</sup> with indication, where appropriate, of the relevant passages <sup>17</sup> | Relevant to Claim No. <sup>18</sup> |
|-----------------------|--|-------------------------------------|
| Y                     | U.S., A, 4,185,618, (COREY) 29 January 1980  | 14-30                               |
| Y                     | U.S., A, 3,641,237, (GOULD et al) 08 February 1972   | 1-7, 9-19, 21-30, 37-38             |
| Y                     | U.S., A, 3,868,447, (KLIMENT) 25 February 1975   | 1-6, 9, 11-18, 21-24, 27-30, 37-38  |
| Y                     | U.S., A, 3,963,685, (ABRAHAMS) 15 June 1976  | 1-5, 9-11, 13-18, 21-22, 24         |
| A,E                   | U.S., A, 4,474,751, (HASLAM et al) 02 October 1984   | 14                                  |
| Y,P                   | U.S., A, 4,409,206, (STRICKER) 11 October 1983   | 1-7, 9-19, 21-38                    |

\* Special categories of cited documents: <sup>15</sup>

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

## **IV. CERTIFICATION**

Date of the Actual Completion of the International Search <sup>9</sup>

November 1984

Date of Mailing of this International Search Report <sup>8</sup>

13 NOV 1984

International Searching Authority <sup>1</sup>

ISA/US

Signature of Authorized Officer <sup>10</sup>

*C Fred Rosenbaum*